Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717827 | 0.90 | MAPK1 (0.61) | RXFP1MAPK1SMN1; SMN2F2ALDH1A1 | |
| SCHEMBL4713091 | 0.89 | ALDH1A1 (0.54) | RXFP1MAPK1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL8312704 | 0.88 | ALDH1A1 (0.48) | RXFP1MAPK1SMN1; SMN2F2ALDH1A1 | |
| SCHEMBL4713822 | 0.81 | L3MBTL1 (0.47) | MAPK1SMN1; SMN2F2ALDH1A1KDM4E | |
| SCHEMBL5739571 | 0.81 | SMN1; SMN2 (0.52) | RXFP1MAPK1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4715685 | 0.79 | MCOLN3 (0.51) | ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL4716756 | 0.77 | ALDH1A1 (0.55) | MAPK1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4714178 | 0.77 | LMNA (0.57) | RXFP1MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4713433 | 0.76 | SMN1; SMN2 (0.54) | MAPK1SMN1; SMN2ALDH1A1MAPTHTT | |
| SCHEMBL8315142 | 0.76 | MAPK1 (0.52) | RXFP1MAPK1SMN1; SMN2F2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | RXFP1 603/4885MAPK1 3513/4885SMN1; SMN2 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.